DelveInsight’s, “Nasopharyngeal Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the Nasopharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nasopharyngeal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Nasopharyngeal Cancer Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Nasopharyngeal Cancer Pipeline Outlook Report

Key Takeaways from the Nasopharyngeal Cancer Pipeline Report

• On 05 August 2025, Genmab conducted a study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers. Participants will have cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable) or relapsed or refractory to prior treatments.
• DelveInsight’s Nasopharyngeal Cancer Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
• The leading Nasopharyngeal Cancer Companies such as ProfoundBio, Chia Tai Tianqing Pharmaceutical Group, Takeda, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical, Ascentage Pharma Group, Akeso and others.
• Promising Nasopharyngeal Cancer Pipeline Therapies such as Apatinib, CC-486, Pemetrexed (Alimta), Docetaxel, Cisplatin, Gemcitabine, Oxaliplatin, Capecitabine, QL1706 and others.

Access DelveInsight’s in-depth Nasopharyngeal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Nasopharyngeal Cancer Clinical Trials and Studies

Nasopharyngeal Cancer Emerging Drugs Profile

• BL-B01D1: SystImmune

BL-B01D1 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by SystImmune, targeting both EGFR and HER3, proteins that are highly expressed in most epithelial tumors. The tetravalent BL-B01D1 possesses two binding domains blocking each Growth Factor Receptor, which both drive cancer cell proliferation and survival. Inheriting the SI-B001 mechanisms of action, BL-B01D1 effectively blocks EGFR and HER3 signals to cancer cells, thereby reducing proliferation and survival signals. Upon antibody-mediated internalization, BL-B01D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death. Currently, the drug is in Phase III stage of its clinical trial for the treatment of nasopharyngeal Carcinoma.

• TAK-500: Takeda

TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of nasopharyngeal cancer.

• APG-5918: Ascentage Pharma

APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid tumors or relapsed or refractory non-Hodgkin’s Lymphoma, nasopharyngeal carcinoma, castration-resistant prostate cancer, B-cell non-Hodgkin lymphoma, IN1-negative malignant rhabdoid tumor, gastric cancer, ovarian clear cell carcinoma, mesothelioma, b cell lymphoma, sickle cell disease, diffuse large B cell lymphoma (DLBCL), SMARCB1-deficient malignant rhabdoid tumor,solid tumor, hematological tumor, anemia and unspecified indication. It is administered through oral route. It acts by targeting polycomb protein EED. Currently, the drug is in Phase I stage of clinical trial for the treatment of nasopharyngeal Carcinoma.

The Nasopharyngeal Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Nasopharyngeal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nasopharyngeal Cancer Treatment.
• Nasopharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nasopharyngeal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nasopharyngeal Cancer market

Explore groundbreaking therapies and clinical trials in the Nasopharyngeal Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Nasopharyngeal Cancer Drugs

Nasopharyngeal Cancer Companies

ProfoundBio, Chia Tai Tianqing Pharmaceutical Group, Takeda, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical, Ascentage Pharma Group, Akeso and others.

Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Nasopharyngeal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Nasopharyngeal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Nasopharyngeal Cancer Pipeline Report

• Coverage- Global
• Nasopharyngeal Cancer Companies- ProfoundBio, Chia Tai Tianqing Pharmaceutical Group, Takeda, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical, Ascentage Pharma Group, Akeso and others.
• Nasopharyngeal Cancer Pipeline Therapies- Apatinib, CC-486, Pemetrexed (Alimta), Docetaxel, Cisplatin, Gemcitabine, Oxaliplatin, Capecitabine, QL1706 and others.
• Nasopharyngeal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nasopharyngeal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Nasopharyngeal Cancer drug development? Find out in DelveInsight’s exclusive Nasopharyngeal Cancer Pipeline Report—access it now! @ Nasopharyngeal Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Nasopharyngeal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nasopharyngeal Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Nasopharyngeal Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. BL-B01D1: SystImmune
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. APG-5918: Ascentage Pharma
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Inactive Products
21. Nasopharyngeal Cancer Key Companies
22. Nasopharyngeal Cancer Key Products
23. Nasopharyngeal Cancer – Unmet Needs
24. Nasopharyngeal Cancer – Market Drivers and Barriers
25. Nasopharyngeal Cancer – Future Perspectives and Conclusion
26. Nasopharyngeal Cancer Analyst Views
27. Nasopharyngeal Cancer Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nasopharyngeal-cancer-pipeline-insight